Now in its third edition, Pharmacology in Clinical Practice has been updated to ensure it remains up-to-date and relevant.

Particular care has been taken to simplify and clarify difficult concepts by explaining the links between pharmacology and physiology by providing definitions of new concepts, and using plain language for ease of understanding. Fundamental concepts, such as pharmacodynamics and pharmacokinetics, are well covered in a matter that is accessible and clear. Individual chapters cover the various systems of the body.

Updates include:

• A colour plate to illustrate the links between pharmacology and physiology
• Additional information on side-effects, contra-indications and patient education for groups of drugs
• A guide on how to access this information, to assist with exam preparation and nursing practice
• An updated chapter on nursing management of drug preparations and treatment
• An updated chapter on clinical applications
• A chapter on the legal framework for dispensing and prescribing.

Native to the Kalahari Desert, Hoodia gordonii is a succulent plant known by generations of indigenous San peoples to have a variety of uses: to reduce hunger, increase energy, and ease breastfeeding. In the global North, it is known as a natural appetite suppressant, a former star of the booming diet industry. In Reinventing Hoodia, Laura Foster explores how the plant was reinvented through patent ownership, pharmaceutical research, the self-determination efforts of indigenous San peoples, contractual benefit sharing, commercial development as an herbal supplement, and bioprospecting legislation. Using a feminist decolonial technoscience approach, Foster argues that although patent law is inherently racialized, gendered, and Western, it offered opportunities for indigenous San peoples, South African scientists, and Hoodia growers to make claims for belonging within the shifting politics of South Africa. This radical interdisciplinary and intersectional account of the multiple materialities of Hoodia illuminates the connections between law, science, and the marketplace, while demonstrating how these domains value certain forms of knowledge and matter differently.

'Bad Science' hilariously exposed the tricks that quacks and journalists use to distort science, becoming a 400,000 copy bestseller. Now Ben Goldacre puts the $600bn global pharmaceutical industry under the microscope. What he reveals is a fascinating, terrifying mess. Doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce unflattering results, the data is simply buried. All of this is perfectly legal. In fact, even government regulators withhold vitally important data from the people who need it most. Doctors and patient groups have stood by too, and failed to protect us. Instead, they take money and favours, in a world so fractured that medics and nurses are now educated by the drugs industry. The result: patients are harmed in huge numbers. Ben Goldacre is Britain's finest writer on the science behind medicine, and 'Bad Pharma' is the book that finally prompted Parliament to ask why all trial results aren't made publicly available - this edition has been updated with the latest news from the select committee hearings. Let the witty and indefatigable Goldacre show you how medicine went wrong, and what you can do to mend it.

This book explores the interplay between regulation and emerging technologies in the context of synthetic biology, a developing field that promises great benefits, and has already yielded fuels and medicines made with designer micro-organisms. For all its promise, however, it also poses various risks. Investigating the distinctiveness of synthetic biology and the regulatory issues that arise, Alison McLennan questions whether synthetic biology can be regulated within existing structures or whether new mechanisms are needed. Adopting an interdisciplinary approach, McLennan draws on diverse areas of law, the science of synthetic biology and the history and sociology of science. She concludes that synthetic biology presents novel regulatory challenges relating to environmental risk, biosafety, biosecurity and intellectual property. These challenges arise from the uniqueness of the science, the nature of its communities of scientists (including citizen scientists or 'biobunks') and the uncertainty surrounding possible hazards. Some scientists see intellectual property protection as a way to push innovation forward (bioentrepreneurs), while others openly share synthetic biology tools such as BioBricks. By understanding the range of regulatory challenges, the book make a case for enhanced regulation that protects us from synthetic biology's risks, whilst capturing its potential to improve our world. Regulation of Synthetic Biology will be essential reading for academics and students in the social sciences and law, as well as for scientists working in synthetic biology, and policymakers in innovation, science and the regulation of these fields.

Rarely in modern British history has a medium-sized company exercised such a dominant influence on an individual industry as Burroughs Wellcome and Co. This book explores the history and development of the company, beginning in the latter part of the 19th century.

In pharmaceutical patent law, the problem of lack of policy direction and inappropriate legal framework is widespread - particularly among jurisdictions with little to no pharmaceutical research or manufacturing. This book aims to inform public policy and influence debate through a comprehensive review of Hong Kong's pharmaceutical patent law. By demonstrating the need for a holistic review of pharmaceutical patent laws and evaluating Hong Kong's system in light of health policy, economic and social factors, Bryan Mercurio recommends changes to the legal framework and constructs a more efficient and effective system for Hong Kong. He thoroughly evaluates the international framework and best practice models to offer a global perspective to each issue before providing local context in the analysis. While the focus of the book is Hong Kong, the analysis on pharmaceutical patent law and policy extends to other jurisdictions facing issues on reforming their national system.

Situated at the crossroads between the history of colonialism, of modern Southeast Asia, and of medical pluralism, this history of medicine and health traces the life of pharmaceuticals in Vietnam under French rule. Laurence Monnais examines the globalization of the pharmaceutical industry, looking at both circulation and consumption, considering access to drugs and the existence of multiple therapeutic options in a colonial context. She argues that colonialism was crucial to the worldwide diffusion of modern medicines and speaks to contemporary concerns regarding over-reliance on pharmaceuticals, drug toxicity, self-medication, and the accessibility of effective medicines. Retracing the steps by which pharmaceuticals were produced and distributed, readers meet the many players in the process, from colonial doctors to private pharmacists, from consumers to various drug traders and healers. Yet this is not primarily a history of medicines as objects of colonial science, but rather a history of medicines as tools of social change.

View the Table of Contents. Read the Introduction.

aStirring firsthand account of the SSRI wars. . . . Healy is a distinguished research and practicing psychiatrist, university professor, frequent expert witness, former secretary of the British Association for Psychopharmacology, and author of three books in the field. Instead of shrinking from commercial involvement, he has consulted for, run clinical trials for, and at times even testified for most of the major drug firms. But when he pressed for answers to awkward questions about side effects, he personally felt Big Pharma's power to bring about a closing of ranks against troublemakers. That experience among others has left him well prepared to puncture any illusions about the companies' benevolence or scruples.a
--"New York Review of Books"

"A compelling story about mystery, deception, death, disappointment, vindication, and uncertainty."
--"The American Psychological Association"

"Healy confirms his status as one longtime thorn in the side of big drug companies, recounting how he was initially enthusiastic about SSRIs but eventually grew concerned about their side effects."
--"Psychology Today"

"Physicians should be aware of Let Them Eat Prozac."
--"JAMA"

"Let Them Eat Prozac is a double-pronged exploration, first of the SSRI drugs used to treat depression, and second of the drug industry."
--"Publishers Weekly"

"Ultimately, the book is about science, society and the power and misuse of commercial promotion. . . . His investigation is impressive."
--"Nature"

"This very important book will demonstrate beyond your worst dreams that the commercial needs of Big Pharma are the natural-born enemyof independent scientific research."
--John Le CarrA(c)

"Healy presents technical matters clearly. This book could not be more timely."
--"Foreword"

"Let Them Eat Prozac is an interesting history. It asks some stimulating and challenging questions, which are still in need of better and more constructive answers."
--"Journal of the American Academy of Child Adolescent Psychiatry"

"In a flood of academic publications and talks, David Healy has issued harsh criticisms of both the pharmaceutical industry in general and the nearly $20-billion-dollar-a-year antidepressant industry in particular."
--"Boston Globe"

"Healy does raise some timely issues."
--"Psychiatric Services"

"Dr. Healy's tenacity in fighting for what he believes in is admirable."
--"E-Streams"

"[Healy is] the leading authority on the history of psychopharmacology."
--"Times Literary Supplement"

aAn alarming book. . . . The most disturbing part of the story Healy tells is not merely about the risks of SSRIs but about the efforts of the pharmaceutical industry to make sure those risks were not uncovered.a
--"Dissent"

"In his timely new book, Healy draws on his extensive experience in antidepressant studies and involvement in legal actions against drug manufacturers. . . . Healy has the advantage of access to internal pharmaceutical industry documents and makes a strong case."
--"Library Journal"

"The author is an excellent historian who offers a gripping interpretation of the role of the pharmaco-industrial complex in the introduction of SSRIs. His recommendation for a funded agency that would carefully evaluate the benefits and harms of marketed drugs is a superb idea andmuch needed."
--Jonathan Cole, Harvard Medical School

"Healy exposes the massive fraud and deception in the production and marketing of antidepressant drugs, the selevtive serotonin reuptake inhibitors (SSRIs)."
--"Choice"

Prozac. Paxil. Zoloft. Turn on your television and you are likely to see a commercial for one of the many selective serotonin reuptake inhibitors (SSRIs) on the market. We hear a lot about them, but do we really understand how these drugs work and what risks are involved for anyone who uses them?

Let Them Eat Prozac explores the history of SSRIs--from their early development to their latest marketing campaigns--and the controversies that surround them. Initially, they seemed like wonder drugs for those with mild to moderate depression. When Prozac was released in the late 1980s, David Healy was among the psychiatrists who prescribed it. But he soon observed that some of these patients became agitated and even attempted suicide. Could the new wonder drug actually be making patients worse?

Healy draws on his own research and expertise to demonstrate the potential hazards associated with these drugs. He intersperses case histories with insider accounts of the research leading to the development and approval of SSRIs as a treatment for depression. Let Them Eat Prozac clearly demonstrates that the problems go much deeper than a side-effect of a particular drug. The pharmaceutical industry would like us to believe that SSRIs can safely treat depression, anxiety, and a host of other mental problems. But, as Let Them Eat Prozac reveals, this "cure" may be worse than the disease.

This invaluable reference presents a comprehensive review of the basic methods for characterizing bioadhesive materials and improving vehicle targeting and uptake-offering possibilities for reformulating existing compounds to create new pharmaceuticals at lower development costs.
Evaluates the unique carrier characteristics of bioadhesive polymers and their power to enhance localization of delivered agents, local bioavailability, and drug absorption and transport
Written by over 50 international experts and reflecting broad knowledge of both traditional bioadhesive strategies and novel clinical applications, Bioadhesive Drug Delivery Systems
discusses mechanical and chemical bonding, polymer-mucus interactions, the effect of surface energy in bioadhesion, polymer hydration, and mucus rheology
analyzes biochemical properties of mucus and glycoproteins, cell adhesion molecules, and cellular interaction with two- and three-dimensional surfaces
covers microbalances and magnetic force transducers, atomic force microscopy, direct measurements of molecular level adhesions, and methods to measure cell-cell interactions
examines bioadhesive carriers, diffusion or penetration enhancers, and lectin-targeted vehicles
describes vaginal, nasal, buccal, ocular, and transdermal drug delivery
reviews bioadhesive interactions with the mucosal tissues of the eye and mouth, and those in the respiratory, urinary, and gastrointestinal tracts
explores issues of product development, clinical testing, and production
and more
Amply referenced with over 1400 bibliographic citations, and illustrated with more than 300 drawings, photographs, tables, and display equations, Bioadhesive Drug Delivery Systems serves as a sound basis for innovation in bioadhesive systems and an excellent introduction to the subject. This unique reference is ideal for pharmaceutical scientists and technologists; chemical, polymer, and plastics engineers; biochemists; physical, surface, and colloid chemists; biologists; and upper-level undergraduate and graduate students in these disciplines.

This three-volume set of Pharmaceutical Dosage Forms: Parenteral Medications is an authoritative, comprehensive reference work on the formulation and manufacture of parenteral dosage forms, effectively balancing theoretical considerations with the practical aspects of their development. As such, it is recommended for scientists and engineers in the pharmaceutical industry and academia, and will also serve as an excellent reference and training tool for regulatory scientists and quality assurance professionals. First published in 1984 (as two volumes) and then last revised in 1993 (when it grew to three volumes), this latest revision will address the plethora of changes in the science and considerable advances in the technology associated with these products and routes of administration. The third edition of this book maintains the features that made the last edition so popular but comprises several brand new chapters, revisions to all other chapters, as well as high quality illustrations. Volume two presents: * Chapters on aseptic facility design, environmental monitoring, and cleanroom operations. * A comprehensive chapter on pharmaceutical water systems. * A discussion of quality attributes of sterile dosage forms, including particulate matter, endotoxin, and sterility testing. * A detailed chapter on processing of parenteral drug products (SVPs and LVPs). * Presentations on widely used sterilization technologies - steam, gas / chemical, radiation, filtration and dry heat. * An in-depth chapter on lyophilization.

During the last five years, clinical research and development costs have risen exponentially without a proportionate increase in the number of new medications. While patient recruitment for clinical studies is only one component in the development of a new medicine or treatment, it is one of the most significant bottlenecks in the overall drug development process. Now, it is imperative that industry leaders see beyond reactive measures and recognize that advancing their approach to patient recruitment is absolutely essential to advancing medicine and continuing the stability of their corporate brand across the globe. Reinventing Patient Recruitment: Revolutionary Ideas for Clinical Trial Success is a definitive guide to planning, implementing, and evaluating recruitment strategies and campaigns globally. The combined experience of the authors provides a depth of perspective and boldness of innovative leadership to set the standards for future patient recruitment programs and practices.This book is a must-have for pharmaceutical, biotechnology, and medical device industry professionals concerned with enrolling for domestic and multinational clinical studies and remaining on time and on budget.

Forecasting for the Pharmaceutical Industry is a definitive guide for forecasters as well as the multitude of decision makers and executives who rely on forecasts in their decision making. In virtually every decision, a pharmaceutical executive considers some type of forecast. This process of predicting the future is crucial to many aspects of the company - from next month's production schedule, to market estimates for drugs in the next decade. The pharmaceutical forecaster needs to strike a delicate balance between over-engineering the forecast - including rafts of data and complex 'black box' equations that few stakeholders understand and even fewer buy into - and an overly simplistic approach that relies too heavily on anecdotal information and opinion. Arthur G. Cook's highly pragmatic guide explains the basis of a successful balanced forecast for products in development as well as currently marketed products. The author explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches. The text is liberally illustrated with tables, diagrams and examples. The final extended case study provides the reader with an opportunity to test out their knowledge. The second edition has been updated throughout and includes a brand new chapter focusing on specialized topics such as forecasting for orphan drugs and biosimilars.

Many countries and regions are actively promoting high technology industries as a means of stimulating the economy. The authors point out that these efforts are not only encouraging economic development, but they also reduce an economy's vulnerability to the negative consequences of world trade. By weaving together the fields of health economics, industrial organisation and industrial development, this book describes the benefits of promoting a country's health industry as a way of stimulating its high-technology industrial capacity. The authors illustrate that the development of a country's health industry not only improves the country's health status, but also promotes an industry with relatively stable, high-wage employment, creates the potential for exporting goods and services, and produces scientific spillovers that will favourably impact other high-technology industries. Health Policy and High-Tech Industrial Development will be of great interest to health policy analysts by showing that health policies have broader implications than merely affecting health systems. Health economists should consider the advantages of viewing a country's health system not only as a unique industry that produces both health care and high-technology goods and services, but that also possesses the ability to stimulate development of a broader array of high-technology industries. Development and industrial economists and policymakers will also see the health sector from this different and innovative perspective.

The pharmaceutical industry must exist to serve the community, but over the years it has engaged repeatedly in corporate crime and anti-social behaviour, with the public footing the bill. This readable study by experts in medicine, law, criminology and public health, with deep experience of the industry, documents problems ranging from false advertising and counterfeiting to corruption, fraud and overpricing. It is a fresh and revealing look at the unacceptable pressures brought to bear on doctors, politicians, patients and the media. Uniquely, the book presents realistic and worldwide solutions for the future, with positive policies encouraging honest dealing, as well as partial privatization of enforcement and a transformation of science policy to develop the medicines that society needs most. The authors examine in turn each of the main facets of the pharmaceutical industry's activities - research, manufacturing, information, distribution and pricing - as well as some questionable aspects of its relationship with society. Offering a considered analysis of pharmaceutical rights and wrongs as they have developed, particularly over the last half-century, this book is rich in new insights for managers in the pharmaceutical industry, regulatory agencies and health agencies.

Award-winning journalist and New York Times bestselling author Gerald Posner traces the heroes and villains of the trillion-dollar-a-year pharmaceutical industry and uncovers how those once entrusted with improving life have often betrayed that ideal to corruption and reckless profiteering-with deadly consequences. Pharmaceutical breakthroughs such as anti biotics and vaccines rank among some of the greatest advancements in human history. Yet exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on pre scription opioids have caused many to lose faith in drug companies. Now, Americans are demanding a national reckoning with a monolithic industry. Pharma introduces brilliant scientists, in-corruptible government regulators, and brave whistleblowers facing off against company exec utives often blinded by greed. A business that profits from treating ills can create far deadlier problems than it cures. Addictive products are part of the industry's DNA, from the days when corner drugstores sold morphine, heroin, and cocaine, to the past two decades of dangerously overprescribed opioids. Pharma also uncovers the real story of the Sacklers, the family that became one of America's wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the center of the opioid crisis. Relying on thousands of pages of government and corporate archives, dozens of hours of interviews with insiders, and previously classified FBI files, Posner exposes the secrets of the Sacklers' rise to power-revelations that have long been buried under a byzantine web of interlocking companies with ever-changing names and hidden owners. The unexpected twists and turns of the Sackler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. Pharma reveals how and why American drug com panies have put earnings ahead of patients.

Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world's poor see little effort to address diseases prevalent in less affluent societies, while the world's wealthy are overusing prescription drugs, risking their health and wasting resources. The debate over health care reform and the ongoing global economic crisis form the backdrop for this extraordinarily timely examination of the global system for the development, production, distribution and use of medicines. The authors are acknowledged experts in the fields of pharmaceutical law and policy, with many years experience advising governments, multilateral organizations and policy-makers on issues involving innovation, access and use of medicines. Supported by a team of independent scientists, doctors and lawyers, they take an insightful look at the issues surrounding global regulation of the pharmaceutical sector, and offer pragmatic suggestions for reform. This book will be of interest to government policy-makers, members of industry, healthcare professionals, teachers, students and lawyers in the fields of public health, intellectual property and international trade.

Multicultural Pharmaceutical Education spotlights methods and theory on how to increase representation of minorities in pharmacy schools and practice settings. Many of the ideas presented in this book are unique, and all provide an opportunity for institutions with few minority students to greatly improve their recruitment and retention efforts geared toward these students. The contributing authors, representing all levels of academia--deans, undergraduate students, vice provosts, executive directors, a National Professor of the Year, and faculty members--have all had experience in some aspect of minority pharmaceutical education. It is through their practical experiences that they offer suggestions and commentary on pharmacy programs of study. Historical accounts or examples of success that could be emulated at other institutions are included. With the help of Multicultural Pharmaceutical Education, colleges and universities and their faculty can forge ahead in attracting and retaining minority students to their pharmacy programs and into the world of pharmacy practice. Structured around four major areas (foundation, commitment, actuation, and conclusion), the authors remove the option of traditional excuses of failure in this important area of education. All those involved in pharmacy education should read this book whether deans, admissions counselors, professors, or students. Multicultural Pharmaceutical Education provides an easy-to-read, practical and theoretical approach to improving the opportunity and quality of education that minority students can achieve in pharmaceutical programs.

"This fascinating and most timely critical medical anthropology study successfully binds two still emergent areas of contemporary anthropological research in the global world: the nature and significant impact of multinational pharmaceutical manufacturers on human social life everywhere, and the contribution of corporations to the fast-paced degradation of our life support system, planet Earth. . . . Focusing on a pharmaceutically-impacted town on the colonized island of Puerto Rico, Dietrich ably demonstrates the value of ethnography carried out in small places in framing the large issues facing humanity." -Merrill Singer, University of Connecticut The production of pharmaceuticals is among the most profitable industries on the planet. Drug companies produce chemical substances that can save, extend, or substantially improve the quality of human life.However, even as the companies present themselves publicly as health and environmental stewards, their factories are a significant source of air and water pollution--toxic to people and the environment. In Puerto Rico, the pharmaceutical industry is the backbone of the island's economy: in one small town alone, there are over a dozen drug factories representing five multinationals, the highest concentration per capita of such factories in the world. It is a place where the enforcement of environmental regulations and the public trust they ensure are often violated in the name of economic development. The Drug Company Next Door unites the concerns of critical medical anthropology with those of political ecology, investigating the multi-faceted role of pharmaceutical corporations as polluters, economic providers, and social actors. Rather than simply demonizing the drug companies, the volume explores the dynamics involved in their interactions with the local community and discusses the strategies used by both individuals and community groups to deal with the consequences of pollution. The Drug Company Next Door puts a human face on a growing set of problems for communities around the world. Accessible and engaging, the book encourages readers to think critically about the role of corporations in everyday life, health, and culture.

Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world's poor see little effort to address diseases prevalent in less affluent societies, while the world's wealthy are overusing prescription drugs, risking their health and wasting resources. The debate over health care reform and the ongoing global economic crisis form the backdrop for this extraordinarily timely examination of the global system for the development, production, distribution and use of medicines. The authors are acknowledged experts in the fields of pharmaceutical law and policy, with many years experience advising governments, multilateral organizations and policy-makers on issues involving innovation, access and use of medicines. Supported by a team of independent scientists, doctors and lawyers, they take an insightful look at the issues surrounding global regulation of the pharmaceutical sector, and offer pragmatic suggestions for reform. This book will be of interest to government policy-makers, members of industry, healthcare professionals, teachers, students and lawyers in the fields of public health, intellectual property and international trade.

IN "THE ANTIDOTE," Barry Werth draws upon unprecedented inside reporting spanning more than two decades to provide a groundbreaking closeup of the upstart pharmaceutical company Vertex and the ferocious but indispensable world of Big Pharma that it inhabits.
In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Werth described the company's tumultuous early days during the AIDS crisis in "The Billion-Dollar Molecule," a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.
The $325 billion-a-year pharmaceutical business is America's toughest and one of its most profitable. It's riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine even after a molecule clears all the hurdles to get to human testing; to the multibillion-dollar cost of ramping up a successful product; to operating in the world's most regulated industry, matched only by nuclear power.
Werth captures the full scope of Vertex's twentyfive- year drive to deliver breakthrough medicines. At a time when America struggles to maintain its innovative edge, "The Antidote" is a powerful inside look at one of the most intriguing and important business stories of recent decades.

This book provides a systematic analysis of the law and practice of EU competition/antitrust law and trade regulation in the pharmaceutical sector. Authored by leading private practitioners, economists, scholars and high-profile competition enforcers, this work provides valuable insider knowledge on the application of competition law and policies to the pharmaceutical industry. Key features include: * Extensive commentary on the legislation and the latest case law and administrative precedents in the pharmaceutical sector, at both EU and national level * Coverage of various key developments including the recent pay-for-delay antitrust investigations, the perennial issues around parallel trade, and an examination of mergers among pharmaceutical companies and medical devices manufacturers * In-depth analysis of topics commonly raised in the pharmaceutical sector including: pricing policies, IP life-cycle management, IP licensing and horizontal cooperation agreements * Key economic and business perspectives to accompany legal analysis, providing the reader with a rounded view of the subject matter. This book will be a useful resource for lawyers and in-house counsel active in the pharmaceutical sector. The information and analysis provided will prepare readers to take on cases and drive the antitrust review of transactions and agreements within the industry. Researchers, economists and civil servants with an interest in competition law and trade regulation can also benefit from the practical insights provided therein.

Lists the necessary steps for meeting compliance requirements during the drug development process. Presents comprehensive approaches for validating analytical methods for pharmaceutical applications. Features key discussions on pre-approval inspections.